• 1.

    De Vriese AS, et al. The atrial fibrillation conundrum in dialysis patients. Am Heart J 2016; 174: 111119. doi: 10.1016/j.ahj.2016.01.010

  • 2.

    Zimmerman D, et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012; 27: 38163822. doi: 10.1093/ndt/gfs416

    • Search Google Scholar
    • Export Citation
  • 3.

    Findlay MD, et al. Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis. Stroke 2015; 46: 24772481. doi: 10.1161/STROKEAHA.115.009095

    • Search Google Scholar
    • Export Citation
  • 4.

    De Vriese AS, Heine G. Anticoagulation management in haemodialysis patients with atrial fibrillation: Evidence and opinion. Nephrol Dial Transplant [published online ahead of print February 27, 2021]. doi: 10.1093/ndt/gfab060; https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfab060/6153972?login=false

    • Search Google Scholar
    • Export Citation
  • 5.

    De Vriese AS, et al. Safety and efficacy of vitamin K antagonists vs rivaroxaban in HD patients with atrial fibrillation: A multicenter randomized controlled trial. J Am Soc Nephrol 2021; 32: 14741483. doi: 10.1681/ASN.2020111566

    • Search Google Scholar
    • Export Citation
  • 6.

    Wald R, et al. Benefits and risks of anticoagulation in dialysis patients with nonvalvular atrial fibrillation. J Am Coll Cardiol 2020; 75:286288. doi: 10.1016/j.jacc.2019.11.033

    • Search Google Scholar
    • Export Citation
  • 7.

    Van Der Meersch H, et al. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. Am Heart J 2017; 184: 3746. doi: 10.1016/j.ahj.2016.09.016

    • Search Google Scholar
    • Export Citation
  • 8.

    Randhawa MS, et al. Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: A systematic review and meta-analysis. JAMA Netw Open 2020; 3:e202175. doi: 10.1001/jamanetworkopen.2020.2175

    • Search Google Scholar
    • Export Citation
  • 9.

    Mookadam M, et al. Novel anticoagulants in atrial fibrillation: A primer for the primary physician. J Am Board Fam Med 2015; 28: 510522. doi: 10.3122/jabfm.2015.04.140297

    • Search Google Scholar
    • Export Citation
  • 10.

    Vu A, et al. Critical analysis of apixaban dose adjustment criteria. Clin Appl Thromb Hemost 2021; 27:10760296211021158. doi: 10.1177/10760296211021158

    • Search Google Scholar
    • Export Citation
  • 11.

    Mavrakanas TA, et al. Apixaban versus no anticoagulation in patients undergoing long-term dialysis with incident atrial fibrillation. Clin J Am Soc Nephrol 2020; 15: 11461154. doi: 10.2215/CJN.11650919

    • Search Google Scholar
    • Export Citation
  • 12.

    Reed D, et al. Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost 2018; 2: 291298. doi: 10.1002/rth2.12083

    • Search Google Scholar
    • Export Citation
  • 13.

    Siontis KC, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018; 138: 15191529. doi: 10.1161/CIRCULATIONAHA.118.035418

    • Search Google Scholar
    • Export Citation
  • 14.

    Chokesuwattanaskul R, et al. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: Meta-analysis. Pacing Clin Electrophysiol 2018; 41: 627634. doi: 10.1111/pace.13331

    • Search Google Scholar
    • Export Citation
  • 15.

    Kuno T, et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J Am Coll Cardiol 2020; 75: 273285. doi: 10.1016/j.jacc.2019.10.059

    • Search Google Scholar
    • Export Citation
  • 16.

    Chan KE, et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation 2015; 13: 972979. doi: 10.1161/CIRCULATIONAHA.114.014113

    • Search Google Scholar
    • Export Citation
  • 17.

    De Vriese AS, et al. Dose-finding study of rivaroxaban in hemodialysis patients. Am J Kidney Dis 2015; 66: 9198. doi: 10.1053/j.ajkd.2015.01.022

    • Search Google Scholar
    • Export Citation
  • 18.

    Wang X, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol 2016; 56: 628636. doi: 10.1002/jcph.628

    • Search Google Scholar
    • Export Citation
  • 19.

    Mavrakanas TA, et al. Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol 2017; 28: 22412248. doi: 10.1681/ASN.2016090980

    • Search Google Scholar
    • Export Citation
  • 20.

    Bohula EA, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 2016; 134:2436. doi: 10.1161/CIRCULATIONAHA.116.022361

    • Search Google Scholar
    • Export Citation

Anticoagulation Management in Patients on Hemodialysis with Atrial Fibrillation More Questions than Answers

Fatima AliFatima Ali, PharmD candidate, is with St. John's University College of Pharmacy and Health Sciences, Jamaica, NY. Mital Jhaveri, PharmD, CACP, is a clinical anticoagulation pharmacist, and Sheila Sarnoski-Brocavich, MS, PharmD, BCGP, is director of pharmacy services with NYC Health+ Hospitals, Queens, Jamaica, NY.

Search for other papers by Fatima Ali in
Current site
Google Scholar
PubMed
Close
,
Mital JhaveriFatima Ali, PharmD candidate, is with St. John's University College of Pharmacy and Health Sciences, Jamaica, NY. Mital Jhaveri, PharmD, CACP, is a clinical anticoagulation pharmacist, and Sheila Sarnoski-Brocavich, MS, PharmD, BCGP, is director of pharmacy services with NYC Health+ Hospitals, Queens, Jamaica, NY.

Search for other papers by Mital Jhaveri in
Current site
Google Scholar
PubMed
Close
, and
Sheila Sarnoski-BrocavichFatima Ali, PharmD candidate, is with St. John's University College of Pharmacy and Health Sciences, Jamaica, NY. Mital Jhaveri, PharmD, CACP, is a clinical anticoagulation pharmacist, and Sheila Sarnoski-Brocavich, MS, PharmD, BCGP, is director of pharmacy services with NYC Health+ Hospitals, Queens, Jamaica, NY.

Search for other papers by Sheila Sarnoski-Brocavich in
Current site
Google Scholar
PubMed
Close
Restricted access
Save